
April 12, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, appointment

April 12, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

April 12, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

April 12, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, BMS, Eisai, Gilead, MSD, Pfizer, ViiV, indivior

April 11, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Inv Dup Del 8p, feature, patient experience, pharma

April 11, 2019 Sales and Marketing Kisqali, NHS, NICE, Novartis, pharma

April 11, 2019 Sales and Marketing Gilead, Jobs, Letairis, Ranexa, redundancy, sales

April 10, 2019 Research and Development, Sales and Marketing Amgen, Evenity, FDA, UCB Pharma, osteoporosis, pharma

April 10, 2019 Research and Development, Sales and Marketing AstraZeneca, Cancer, MSD, breast cancer, lynparza, pharma

April 9, 2019 Manufacturing and Production, Sales and Marketing Epilepsy Society, UK, brexit, epilepsy, market access, pharma

April 9, 2019 Manufacturing and Production, Sales and Marketing Dravet Syndrome, FDA, Fintepla, Zogenix

April 8, 2019 Manufacturing and Production, Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, liver cancer, pharma

April 8, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, appointment, kymab, pharma

April 8, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing feature, pharma, real world data, real world evidence, real-world data, real-world evidence

April 8, 2019 Research and Development, Sales and Marketing Astellas, Cancer, NHS, NICE, UK, pharma, prostate cancer